– Interview with Michael Keech, Director, Pharmaceutical and Life Sciences Advisory Services Group, PricewaterhouseCoopers

Previous articleGSK Divests U.S. Rights for Depression Drug to Biovail for $510M
Next articleVernalis and Servier Sign Second Cancer Drug Discovery Agreement